A Phase 1/2 interventional study of SAR302503 (TG101348) in Myelofibrosis, sponsored by Bristol-Myers Squibb. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 1 of them phase 3. Primary Myelofibrosis · Bristol-Myers Squibb.
Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 1/2, and was the 2nd registered.
628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →1 of the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is close to the median of 43 across 492 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 92 across the 10 interventional studies, 150 across the 3 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety, tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: SAR302503 (TG101348)
orally administered, once a day
Clinical Response (IWG-MRT) - Best Overall Response
Best response categories per IWG-MRT response criteria across studies TED12037 and TED12015 combined. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission; SD indicates no meaningful change; and PD indicates disease worsening.
Time frame: From enrollment to date of first objective response, or death due to any cause (up to approximately 52 months)
Time to Any Response
Time to any first response (CR/PR/CI); median and range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.
Time frame: From enrollment to date of first objective response, or death due to any cause (up to approximately 56 months)
Duration of Response
Duration of response (days); range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.
Time frame: From enrollmen to death due to any cause (up to approximately 52 months)
Spleen Size at Baseline (TED12037)
Palpable spleen size in cm below the left costal margin at baseline of TED12037.
Time frame: Baseline
Transfusion Dependence at Baseline (TED12037)
Transfusion dependence defined as RBC transfusion within 56 days before baseline of TED12037.
Time frame: Baseline
Of the 59 patients enrolled in TED12037, 43 patients continued treatment in TED12015.
| Milestone | SAR302503 |
|---|---|
| Started | 43 |
| Completed | 12 |
| Not completed | 31 |
Best response categories per IWG-MRT response criteria across studies TED12037 and TED12015 combined. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission; SD indicates no meaningful change; and PD indicates disease worsening.
| Participants | SAR302503 |
|---|---|
| Complete Remission (CR) | 1 |
| Partial Remission (PR) | 0 |
| Clinical Improvement (CI) | 31 |
| Stable Disease | 11 |
| Progressive Disease | 0 |
Time to any first response (CR/PR/CI); median and range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.
| days | SAR302503 |
|---|---|
| Time to Any Response | 140 ± 77 |
Duration of response (days); range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.
| days | SAR302503 |
|---|---|
| Duration of Response | NA (13 to 1537) |
Palpable spleen size in cm below the left costal margin at baseline of TED12037.
| cm | SAR302503 |
|---|---|
| Spleen Size at Baseline (TED12037) | 18.7 ± 6.40 |
Transfusion dependence defined as RBC transfusion within 56 days before baseline of TED12037.
| Participants | SAR302503 |
|---|---|
| No | 28 |
| Yes | 14 |
Collected over AEs/SAEs are collected from the first dose date until the last dose date + 30 days (up to approximately 55 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAR302503 | 8/43 (18.6%) | 23/43 (53.5%) | 43/43 (100%) |
| Event | SAR302503 |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/43 |
| PneumoniaInfections and infestations | 3/43 |
| NeutropeniaBlood and lymphatic system disorders | 2/43 |
| DiarrheaGastrointestinal disorders | 2/43 |
| NauseaGastrointestinal disorders | 2/43 |
| VomitingGastrointestinal disorders | 2/43 |
| PyrexiaGeneral disorders | 2/43 |
| Clostridium difficile colitisInfections and infestations | 2/43 |
| Subdural hematomaInjury, poisoning and procedural complications | 2/43 |
| DehydrationMetabolism and nutrition disorders | 2/43 |
| Event | SAR302503 |
|---|---|
| (N=3) All Doses (N=43) InvestigationsInjury, poisoning and procedural complications | 41/43 |
| DiarrhoeaGastrointestinal disorders | 35/43 |
| NauseaGastrointestinal disorders | 35/43 |
| AnaemiaBlood and lymphatic system disorders | 34/43 |
| VomitingGastrointestinal disorders | 32/43 |
| ThrombocytopeniaBlood and lymphatic system disorders | 30/43 |
| Blood creatinine increasedInjury, poisoning and procedural complications | 24/43 |
| Aspartate aminotransferase increasedInjury, poisoning and procedural complications | 20/43 |
| FatigueGeneral disorders and administration site conditions | 19/43 |
| Oedema peripheralGeneral disorders and administration site conditions | 19/43 |
| Age, Continuous(years) | SAR302503 |
|---|---|
| Mean | 63.8 ± 10.0 |
| Sex: Female, Male(Participants) | SAR302503 |
|---|---|
| Female | 17 |
| Male | 26 |
Ran from Jul 2008 to primary completion in May 2014, 69 months.
Results were first posted in Oct 2026, 12 years 4 months after primary completion. A results delay was requested in Feb 2016.
Of 27 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's 69 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fedratinib